BUDAPEST, Hungary, Oct. 18, 2022 /PRNewswire/ Between the 15-18th of October 2022, during the 35th Annual Meeting of the European College of Neuropsychopharmacology (ECNP), new analyses of
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions
A real-world analysis suggests that clozapine or antipsychotic polytherapy are most effective in reducing the risk for substance use disorder in adults with schizophrenia.
Solitary drinking in adolescence and young adulthood is a strong predictor of alcohol use disorder by age 35, results of a new longitudinal study show.